Skip to content

Study · Randomized controlled trial · 2025

4 results

Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.

Mather KJ, Mari A, Weerakkody G, Heise T, DeVries JH, Urva S, Coskun T, Milicevic Z, Haupt A, Thomas MK

Diabetes, obesity & metabolism6 Jan 2025Cited by 10 (Europe PMC)

PMID39762971 (opens in a new tab)DOI10.1111/dom.16159 (opens in a new tab)PepBankPUB-39762971
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, tirzepatide 15 mg improved clamp-measured insulin sensitivity more than semaglutide 1 mg.

    In plain wordsIn adults with type 2 diabetes, tirzepatide improved the body's response to insulin more than semaglutide did.

    Peptide
    Tirzepatide
    Outcome
    IncreaseInsulin sensitivity by hyperinsulinemic euglycemic clamp versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide was associated with a greater improvement than semaglutide in insulin sensitivity assessed using hyperinsulinemic euglycemic clamps (p < 0.001).
    1 context sentence
    Summary · context
    We conducted a post hoc exploratory analysis of a 28-week, double-blind, randomized trial in people with type 2 diabetes treated with metformin, randomized to tirzepatide 15 mg, semaglutide 1 mg or placebo.
  2. 02HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes on metformin, tirzepatide-induced improvements in insulin sensitivity were associated with percent change in weight.

    In plain wordsIn adults with type 2 diabetes, better insulin sensitivity on tirzepatide was linked to more weight loss.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCorrelation of insulin sensitivity improvement with percent weight change
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Measurements

    Correlation coefficient R
    −0.656
    tirzepatide

    Source sentences

    Summary
    With tirzepatide, improvements in insulin sensitivity were associated with percent change in weight (R = -0.656, p < 0.0001).
    1 context sentence
    Summary · context
    We conducted a post hoc exploratory analysis of a 28-week, double-blind, randomized trial in people with type 2 diabetes treated with metformin, randomized to tirzepatide 15 mg, semaglutide 1 mg or placebo.
  3. 03HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes on metformin, with semaglutide the correlation between change in insulin sensitivity and percent weight change was weaker and not statistically significant.

    In plain wordsIn adults with type 2 diabetes, the link between insulin sensitivity change and weight loss on semaglutide was weaker, and not statistically significant.

    Peptide
    Semaglutide
    Outcome
    No significant changeCorrelation of insulin sensitivity improvement with percent weight change
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · 28 weeksAs given in this study (human).

    Measurements

    Correlation coefficient R
    −0.268
    semaglutide

    Source sentences

    Summary
    With semaglutide, change in insulin sensitivity was less strongly correlated with percent change in weight (R = -0.268, p = 0.0820; p = 0.0242 vs. tirzepatide).
    1 context sentence
    Summary · context
    We conducted a post hoc exploratory analysis of a 28-week, double-blind, randomized trial in people with type 2 diabetes treated with metformin, randomized to tirzepatide 15 mg, semaglutide 1 mg or placebo.
  4. 04HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes on metformin, the slope of M value change against weight change differed statistically between tirzepatide and semaglutide.

    In plain wordsIn adults with type 2 diabetes, insulin sensitivity changed differently per unit of weight loss on tirzepatide than on semaglutide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSlope of M value change versus weight change compared with semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    In regression analyses, the slope of the relationship between change in M value and change in weight was statistically different between semaglutide and tirzepatide (p = 0.0461).
    1 context sentence
    Summary · context
    We conducted a post hoc exploratory analysis of a 28-week, double-blind, randomized trial in people with type 2 diabetes treated with metformin, randomized to tirzepatide 15 mg, semaglutide 1 mg or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.